Cited by 2,445PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 159 of the 160 references it cites were found in a registry or an index.

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, Jeffrey A.·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

There are ample genetic and laboratory studies that suggest the PI3K-Akt pathway is vital to the growth and survival of cancer cells. Inhibitors targeting this pathway are entering the clinic at a rapid pace. In this Review, the therapeutic potential of drugs targeting PI3K-Akt signalling for the treatment of cancer is discussed. I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clinical development.

Integrity signals

Registry

Crossref · 10.1038/nrc2664

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 retracted

RETRACTED: Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling
She, Q., Chandarlapaty, S., Ye, Q., Lobo, J. M., Haskell, K., Leander, K. R., Defeo-Jones, D., Huber, H. E., & Rosen, N. X. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003065 · Cited by 313
Retracted
Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma
Garcia-Pedrero, J. M., García‐Carracedo, D., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S., & González, M. V. (2004) · International Journal of Cancer · doi:10.1002/ijc.20711 · Cited by 235
Retracted
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation

Flagged first, then by citations

Show all 160 references

1 of the 160 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Bi, L., Okabe, I., Bernard, D. J. & Nussbaum, R. L. Early embryonic lethality in mice deficient in the p110b catalytic subunit of PI3-kinase. Mamm. Genome 13, 169–172 (2002).

Sorted by citations

Items 801–900 of 1,005

Integrin/Fak/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes
Beauséjour, M., Noël, D., Thibodeau, S., Bouchard, V., Harnois, C., Beaulieu, J., Demers, M., & Vachon, P. H. (2012) · APOPTOSIS · doi:10.1007/s10495-012-0713-6 · Cited by 47
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations
Park, E., Park, J., Han, S., Im, S., Kim, T.-Y., Oh, D., & Bang, Y. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1290 · Cited by 47
A preferential p110α/γ PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-κB-dependent manner
Dagia, N. M., Agarwal, G., Kamath, D. V., Chetrapal-Kunwar, A., Gupte, R. D., Jadhav, M. G., Dadarkar, S. S., Trivedi, J., Kulkarni‐Almeida, A., Kharas, F., et al. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00461.2009 · Cited by 47
Diet-Induced Unresolved ER Stress Hinders KRAS-Driven Lung Tumorigenesis
Ramadori, G., Konstantinidou, G., Venkateswaran, N., Biscotti, T., Morlock, L., Galiè, M., Williams, N. S., Luchetti, M. M., Santinelli, A., Scaglioni, P. P., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.11.020 · Cited by 50
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
Kim, A., Park, S., Lee, J. J., Jang, W., Lee, S., Kang, H. J., & Lee, S.-S. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.02.010 · Cited by 47
ROS-mediated EB1 phosphorylation through Akt/GSK3β pathway: implication in cancer cell response to microtubule-targeting agents
Grand, M. L., Rovini, A. M. F., Bourgarel‐Rey, V., Honoré, S., Bastonero, S., Braguer, D., & Carre, M. (2014) · Oncotarget · doi:10.18632/oncotarget.1982 · Cited by 48
2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors
Patel, L., Chandrasekhar, J., Evarts, J., Haran, A. C., Ip, C., Kaplan, J. A., Kim, M., Koditek, D., Lad, L., Lepist, E., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00213 · Cited by 47
Exosomes in Cancer Disease
Zöller, M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3204-7_7 · Cited by 48
Volume of high-risk intratumoral subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma
Cui, Y., Ren, S., Tha, K. K., Wu, J., Shirato, H., & Li, R. (2017) · European Radiology · doi:10.1007/s00330-017-4751-x · Cited by 50
Role of GSK-3β in Regulation of Canonical Wnt/β-catenin Signaling and PI3-K/Akt Oncogenic Pathway in Colon Cancer
Jain, S., Ghanghas, P., Rana, C., & Sanyal, S. N. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1337783 · Cited by 47
Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2- a ]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors
Fan, Y., Li, W., Liu, D., Bai, M., Song, H., Xu, Y., Lee, S.-K., Zhou, Z., Wang, J., & Ding, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.074 · Cited by 47
Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis
Lin, S., Jin, J., Liu, Y., Tian, H., Zhang, Y., Fu, R., Zhang, J., Wang, M., Du, T., Ji, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00969 · Cited by 47
Neddylation-Independent Activities of MLN4924
Mao, H., & Sun, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_21 · Cited by 45
Novel targeted treatment options for advanced cholangiocarcinoma
Mahipal, A., Kommalapati, A., Tella, S. H., Lim, A., & Kim, R. D. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1512581 · Cited by 46
Metformin prevents aggressive ovarian cancer growth driven by high-energy diet: similarity with calorie restriction
Al-Wahab, Z. R., Mert, İ., Tebbe, C., Chhina, J., Hijaz, M., Morris, R. T., Ali‐Fehmi, R., Giri, S., Munkarah, A. R., & Rattan, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3434 · Cited by 47
miR-221/222 control luminal breast cancer tumor progression by regulating different targets
Dentelli, P., Traversa, M., Rosso, A., Togliatto, G., Olgasi, C., Marchiò, C., Provero, P., Lembo, A., Bon, G., Annaratone, L., et al. (2014) · Cell Cycle · doi:10.4161/cc.28758 · Cited by 46
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer
Moestue, S. A., Dam, C. G., Gorad, S. S., Kristian, A., Bofin, A. M., Mælandsmo, G. M., Engebråten, O., Gribbestad, I. S., & Bjørkøy, G. (2013) · Breast Cancer Research · doi:10.1186/bcr3391 · Cited by 46
Preparation of S14161 and its analogues and the discovery of 6-bromo-8-ethoxy-3-nitro-2H-chromene as a more potent antitumor agent in vitro
Yin, S., Shi, M., Kong, T., Zhang, C., Han, K., Cao, B., Zhang, Z., Du, X., Tang, L.-Q., Mao, X., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.097 · Cited by 46
Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice
García‐Martínez, J. M., Wullschleger, S., Preston, G., Guichard, S. M., Fleming, S., Alessi, D. R., & Duce, S. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.83 · Cited by 47
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer
Blagden, S. P., Olmin, A., Josephs, D. H., Stavraka, C., Zivi, A., Pinato, D. J., Anthoney, A., Decordova, S., Swales, K. E., Riisnaes, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1315 · Cited by 46
p53 is a major component of the transcriptional and apoptotic program regulated by PI 3-kinase/Akt/GSK3 signaling
Nayak, G., & Cooper, G. M. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.138 · Cited by 46
Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma
Yang, C., Zhang, Y., Zhang, Y., Zhang, Z., Peng, J.-H., Li, Z., Han, L., You, Q.-J., Chen, X., Rao, X., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3100 · Cited by 45
Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models
Xu, S., Li, S., Guo, Z., Luo, J. R., Ellis, M. J., & Ma, C. X. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0159 · Cited by 46
Expression, activation, and role of AKT isoforms in the uterus
Fabi, F., & Asselin, É. (2014) · Reproduction · doi:10.1530/rep-14-0270 · Cited by 46
Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics
Josephs, D. H., & Sarker, D. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30529 · Cited by 49
PIK3CAH1047R and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
Cheng, H.-L., Liu, P.-X., Ohlson, C. E., Xu, E., Symonds, L., Isabella, A., Muller, W., Lin, N., Krop, I., Roberts, T., et al. (2015) · Oncogene · doi:10.1038/onc.2015.377 · Cited by 40
Quercetin reverses the doxorubicin resistance of prostate cancer cells by downregulating the expression of c‑met
Yan, S., Xie, B., Liang, Z. C., & Chen, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.7561 · Cited by 46
PI3K inhibition to overcome endocrine resistance in breast cancer
Keegan, N. M., Gleeson, J. P., Hennessy, B. T., & Morris, P. G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1417384 · Cited by 48
SIRT4 Suppresses Doxorubicin-Induced Cardiotoxicity by Regulating the AKT/mTOR/Autophagy Pathway
He, L., Wang, J., Yang, Y., Zou, P., Xia, Z., & Li, J. (2022) · Toxicology · doi:10.1016/j.tox.2022.153119 · Cited by 46
Myricetin induces apoptosis and autophagy in human gastric cancer cells through inhibition of the PI3K/Akt/mTOR pathway
Han, S., Lee, J.-H., Woo, J., Jung, G.-H., Jung, S., Han, E.-J., Kim, B., Cho, S. D., Nam, J., Hwan, J., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09309 · Cited by 45
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma
Birner, P., Pusch, S., Christov, C., Mihaylova, S., Toumangelova‐Uzeir, K., Natchev, S., SCHOPPMANN, S. F., Tchorbanov, A. I., Streubel, B., Tuettenberg, J., et al. (2014) · Cancer · doi:10.1002/cncr.28732 · Cited by 46
The Synthetic Cannabinoid WIN 55,212-2 Sensitizes Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Induced Apoptosis by Activating p8/CCAAT/Enhancer Binding Protein Homologous Protein (CHOP)/Death Receptor 5 (DR5) Axis
Pellerito, O., Calvaruso, G., Portanova, P., BLASIO, A. D., Santulli, A., Vento, R., Tesoriere, G., & Giuliano, M. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.062257 · Cited by 45
Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease
Marwick, J. A., Chung, K. F., & Adcock, I. M. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465809352792 · Cited by 45
Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer
Yuan, H., Chen, J., Liu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3354 · Cited by 45
A view on EGFR-targeted therapies from the oncogene-addiction perspective
Pérez, R., Crombet, T., de León, J., & Moreno, E. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00053 · Cited by 46
Degradation of Akt using protein-catalyzed capture agents
Henning, R. K., Varghese, J. O., Das, S., Nag, A., Tang, G. Y., Tang, K., Sutherland, A. M., & Heath, J. R. (2016) · Journal of Peptide Science · doi:10.1002/psc.2858 · Cited by 45
Fluid shear stress induces epithelial-mesenchymal transition (EMT) in Hep-2 cells
Liu, S., Zhou, F., Shen, Y., Zhang, Y., Yin, H., Zeng, Y., Liu, J., Yan, Z., & Liu, X. (2016) · Oncotarget · doi:10.18632/oncotarget.8765 · Cited by 45
Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule
Cheng, X., Merz, K., Vatter, S., Zeller, J., Muehlbeyer, S., Thommet, A., Christ, J., Wölfl, S., & Eisenbrand, G. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00324 · Cited by 45
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency
Yang, L., Yang, G., Ding, Y., Huang, Y., Liu, S., Zhou, L., Wei, W., Wang, J., & Hu, G. (2018) · Oncology Reports · doi:10.3892/or.2018.6445 · Cited by 45
The Role of PI3K in Met Driven Cancer: A Recap
Hervieu, A., & Kermorgant, S. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00086 · Cited by 47
LHPP suppresses bladder cancer cell proliferation and growth via inactivating AKT/p65 signaling pathway
Li, Y., Zhang, X., Zhou, X., & Zhang, X. (2019) · Bioscience Reports · doi:10.1042/bsr20182270 · Cited by 45
Distinct diagnostic and prognostic values of γ‑aminobutyric acid type A receptor family genes in patients with colon adenocarcinoma
Yan, L., Gong, Y., Shao, M., Ruan, G., Xie, H., Liao, X., Wang, X., Han, Q., Zhou, X., Zhu, L., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11573 · Cited by 46
Repeated radon exposure induced lung injury and epithelial–mesenchymal transition through the PI3K/AKT/mTOR pathway in human bronchial epithelial cells and mice
Chen, H., Chen, N., Li, F., Sun, L., Du, J., Chen, Y., Cheng, F., Li, Y., Tian, S., Jiang, Q., et al. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.09.008 · Cited by 45
Taxifolin, Extracted from Waste Larix olgensis Roots, Attenuates CCl4-Induced Liver Fibrosis by Regulating the PI3K/AKT/mTOR and TGF-β1/Smads Signaling Pathways
Liu, X., Liu, W., Ding, C., Zhao, Y., Chen, X., Dong, L., Zheng, Y., & Cheng, Z. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s281369 · Cited by 46
miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation
Wuerkenbieke, D., Wang, J., Li, Y., & Ma, C. (2015) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3742-x · Cited by 45
Selective anticancer agents suppress aging in Drosophila
Danilov, A., Shaposhnikov, M. V., Plyusnina, E., Kogan, V., Fedichev, P. O., & Moskalev, A. (2013) · Oncotarget · doi:10.18632/oncotarget.1272 · Cited by 46
Are we on the brink of nonsurgical treatment for ameloblastoma?
Sauk, J. J., Nikitakis, N. G., & Scheper, M. A. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2010.01.024 · Cited by 44
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Mezynski, J., Farrelly, A. M., Cremona, M., Carr, A., Morgan, C., Workman, J. A., Armstrong, P., McAuley, J., Madden, S. F., Fay, J., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02842-1 · Cited by 44
Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions
Yardley, D. A. (2013) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s10071 · Cited by 45
Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions
Troxell, M. L., Brunner, A. L., Neff, T. L., Warrick, A., Beadling, C., Montgomery, K. D., Zhu, S., Corless, C. L., & West, R. B. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.55 · Cited by 46
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation
Fang, D. D., Zhang, C. C., Gu, Y., Jani, J. P., Cao, J. Q., Tsaparikos, K. E., Yuan, J., Thiel, M., Jackson-Fisher, A. J., Zong, Q., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067258 · Cited by 44
The Role of PTEN in Tumor Angiogenesis
Rodriguez, S., & Huynh‐Do, U. (2011) · Journal of Oncology · doi:10.1155/2012/141236 · Cited by 44
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin
Ou, D., Lee, B.-S., Lin, L., Liou, J., Liao, S., Hsu, C., & Cheng, A. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-2 · Cited by 44
An inducible knock-out mouse to model cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias
Mirantes, C., Eritja, N., Dosil, M. A., Santacana, M., Pallarés, J., Gatius, S., Bergadà, L., Maiques, Ó., Matías‐Guiu, X., & Dolcet, X. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.011445 · Cited by 44
miRNA-542-3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation
Ma, T., Lu, Y., & Zhang, J. (2015) · Oncology Reports · doi:10.3892/or.2015.3713 · Cited by 44
NEDD4L Protein Catalyzes Ubiquitination of PIK3CA Protein and Regulates PI3K-AKT Signaling
Wang, Z., Dang, T., Liu, T., Chen, S., Li, L., Huang, S. M., & Fang, M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.726083 · Cited by 48
Thyroid Hormone Controls Breast Cancer Cell Movement via Integrin αV/β3/SRC/FAK/PI3-Kinases
Flamini, M. I., Uzair, I., Pennacchio, G. E., Neira, F. J., Mondaca, J. M., Cuello-Carrión, F. D., Jahn, G. A., Simoncini, T., & Sanchez, A. M. (2017) · Hormones and Cancer · doi:10.1007/s12672-016-0280-3 · Cited by 44
Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment
Győri, D., Chessa, T. A. M., Hawkins, P. T., & Stephens, L. (2017) · Cancers · doi:10.3390/cancers9030024 · Cited by 45
Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors
Zhan, M., Deng, Y., Zhao, L., Yan, G., Wang, F., Tian, Y., Zhang, L., Jiang, H., & Chen, Y. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00357 · Cited by 44
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
Ali, M., Kaltenbrun, E., Anderson, G. R., Stephens, S. J., Arena, S., Bardelli, A., Counter, C. M., & Wood, K. C. (2017) · Nature Communications · doi:10.1038/ncomms15617 · Cited by 45
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas
Cheson, B. D., O'Brien, S. M., Ewer, M. S., Goncalves, M. D., Farooki, A., Lenz, G., Yu, A. F., Fisher, R. I., Zinzani, P. L., & Dreyling, M. H. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.11.021 · Cited by 44
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
Aasen, S. N., Parajuli, H., Hoang, T., Feng, Z., Stokke, K., Wang, J., Roy, K., Bjerkvig, R., Knappskog, S., & Thorsen, F. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174235 · Cited by 44
ROS and Lipid Droplet accumulation induced by high glucose exposure in healthy colon and Colorectal Cancer Stem Cells
Tirinato, L., Pagliari, F., Franco, S. D., Sogne, E., Marafioti, M. G., Jansen, J., Falqui, A., Todaro, M., Candeloro, P., Liberale, C., et al. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.09.010 · Cited by 42
CPSF7 regulates liver cancer growth and metastasis by facilitating WWP2-FL and targeting the WWP2/PTEN/AKT signaling pathway
Fang, S., Zhang, D., Weng, W., Lv, X., Zheng, L., Chen, M., Fan, X., Mao, J., Mao, C., Ye, Y., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118624 · Cited by 44
Enhanced radiosensitivity of head and neck squamous cell carcinoma cells by β1 integrin inhibition
Eke, I., Dickreuter, E., & Cordes, N. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.05.009 · Cited by 44
Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review
Wang, Y., & Tortorella, M. D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114039 · Cited by 44
Circular RNAs in cholangiocarcinoma
Liao, W., Feng, Q., Liu, H., Du, J., Chen, X., & Zeng, Y. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215980 · Cited by 44
Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
Wang, H., Zhou, R., Xu, F., Yang, K., Zheng, L., Zhao, P., Shi, G., Dai, L., Xu, C., Yu, L., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00385-8 · Cited by 48
Platelet-activating factor receptor-mediated PI3K/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma
Chen, J., Lan, T., Zhang, W., Dong, L., Kang, N., Zhang, S., Fu, M., Liu, B., Liu, K., Zhang, C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.434 · Cited by 43
The PI3K/Akt Signaling Pathway Mediates the High Glucose-Induced Expression of Extracellular Matrix Molecules in Human Retinal Pigment Epithelial Cells
Qin, D., Zhang, G., Xu, X., & Wang, L. (2015) · Journal of Diabetes Research · doi:10.1155/2015/920280 · Cited by 43
Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway
Li, W., Chen, Z., Gong, F.-R., Zong, Y., Chen, K., Li, D., Yin, H. X., Duan, W., Miao, Y., Tao, M., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.014 · Cited by 43
Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
Lin, S., Huang, Y., Lin, J., Chou, T., Hsueh, C., & Wong, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046726 · Cited by 43
Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone
Khanfar, M. A., AbuKhader, M., Alqtaishat, S., & Taha, M. O. (2013) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2013.02.009 · Cited by 45
Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers
James, A. D., Blumenstein, L., Glaenzel, U., Jin, Y., Demailly, A., Jakab, A., Hansen, R., Hazell, K., Mehta, A., Trandafir, L., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2842-4 · Cited by 43
Restoration of miR‐152 expression suppresses cell proliferation, survival, and migration through inhibition of AKT–ERK pathway in colorectal cancer
Ghazanchaei, A., Mansoori, B., Mohammadi, A., Biglari, A., & Baradaran, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26891 · Cited by 43
p27 transcriptionally coregulates cJun to drive programs of tumor progression
Yoon, H., Kim, M., Jang, K., Shin, M., Besser, A. H., Xiao, X., Zhao, D., Wander, S. A., Briegel, K. J., Morey, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817415116 · Cited by 43
Fisetin and 5‐fluorouracil: Effective combination for PIK3CA‐mutant colorectal cancer
Khan, N., Jajeh, F., Eberhardt, E. L., Miller, D. D., Albrecht, D. M., Doorn, R. R. V., Hruby, M. D., Maresh, M. E., Clipson, L. J., Mukhtar, H., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32367 · Cited by 46
Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer
Feng, W. W., & Kurokawa, M. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.100 · Cited by 44
Effects of partial fish meal replacement with two fermented soybean meals on the growth of and protein metabolism in the Chinese mitten crab (Eriocheir sinensis)
Xu, C.-Y., Liu, W.-B., Zhang, D.-D., Liu, J.-D., Zheng, X.-C., Zhang, C.-Y., Yao, J., Zhu, C.-M., & Chi, C. (2020) · Aquaculture Reports · doi:10.1016/j.aqrep.2020.100328 · Cited by 45
Acid ceramidase induces sphingosine kinase 1/S1P receptor 2-mediated activation of oncogenic Akt signaling
Beckham, T. H., Cheng, J. C., Lü, P., Shao, Y., Troyer, D. A., Lance, R. A., Marrison, S. T., Norris, J. S., & Liu, X. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.14 · Cited by 42
Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth
Mouradian, M. H., Kikawa, K. D., Johnson, E. D., Beck, K., & Pardini, R. S. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.12.001 · Cited by 42
Emerging targeted therapies for bladder cancer: a disease waiting for a drug
Dovedi, S. J., & Davies, B. R. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9192-9 · Cited by 42
New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways
Dasari, A. N., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2283 · Cited by 42
Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
Ewald, F., Nörz, D. S., Grottke, A., Bach, J., Herzberger, C., Hofmann, B. T., Nashan, B., & Jücker, M. (2015) · Journal of Cancer · doi:10.7150/jca.12452 · Cited by 43
Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells
Li, T., Chen, X., Chen, X., Ma, D., Leung, C. H., & Lu, J. (2016) · Scientific Reports · doi:10.1038/srep37997 · Cited by 45
Effect of surface chemistry on the integrin induced pathway in regulating vascular endothelial cells migration
Shen, Y., Gao, M., Ma, Y., Yu, H., Cui, F., Gregersen, H. N., Yu, Q., Wang, G., & Liu, X. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.12.019 · Cited by 42
A phase I trial of MK‐2206 in children with refractory malignancies: A Children's Oncology Group study
Fouladi, M., Perentesis, J. P., Phillips, C. L., Leary, S. E. S., Reid, J. M., McGovern, R. M., Ingle, A. M., Ahern, C. H., Ames, M. M., Houghton, P. J., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25023 · Cited by 41
Colorectal Cancer: From Genetic Landscape to Targeted Therapy
Bali, M. E., Bakkach, J., & Mechita, M. B. (2021) · Journal of Oncology · doi:10.1155/2021/9918116 · Cited by 43
The treatment landscape of triple-negative breast cancer
Hu, Y., Wang, C., Liang, H., Li, J., & Yang, Q. (2024) · Medical Oncology · doi:10.1007/s12032-024-02456-9 · Cited by 42
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations
Kehr, E. L., Jorns, J. M., Ang, D. C., Warrick, A., Neff, T. L., Degnin, M., Lewis, R., Beadling, C., Corless, C. L., & Troxell, M. L. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.03.012 · Cited by 41
Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia
Cuesta‐Mateos, C., López-Giral, S., Alfonso-Pérez, M., de Soria, V. G.-G., Loscertales, J., Guash, S., Beltrán, A. E., Zapata, J. M., & Muñoz‐Calleja, C. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.05.003 · Cited by 41
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
Alvarado, Y., Mita, M. M., Vemulapalli, S., Mahalingam, D., & Mita, A. C. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0178-5 · Cited by 41
Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression
Nemazanyy, I., Espeillac, C., Pende, M., & Panasyuk, G. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130034 · Cited by 41
A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors
Blumenthal, G. M., Gills, J. J., Ballas, M. S., Bernstein, W. B., Komiya, T., DeChowdhury, R., Morrow, B., Root, H., Chun, G., Helsabeck, C. B., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2415 · Cited by 41
PI3K regulates branch initiation and extension of cultured mammary epithelia via Akt and Rac1 respectively
Zhu, W., & Nelson, C. M. (2013) · Developmental Biology · doi:10.1016/j.ydbio.2013.04.029 · Cited by 41
Pten -Null Tumors Cohabiting the Same Lung Display Differential AKT Activation and Sensitivity to Dietary Restriction
Curry, N. L., Mino-Kenudson, M. A., Oliver, T. G., Yilmaz, Ö. H., Yilmaz, V. O., Moon, J. Y., Jacks, T., Sabatini, D. M., & Kalaany, N. Y. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0507 · Cited by 42
Progesterone modulates endothelial progenitor cell ( EPC ) viability through the CXCL 12/ CXCR 4/ PI 3K/Akt signalling pathway
Yu, P., Zhang, Z., Li, S., Wen, X., Quan, W., Tian, Q., Chen, J., Zhang, J., & Jiang, R. (2016) · Cell Proliferation · doi:10.1111/cpr.12231 · Cited by 41
MicroRNA–target cross-talks: Key players in glioblastoma multiforme
Toraih, E. A., Aly, N. M., Abdallah, H. Y., Alqahtani, S. A. M., Shaalan, A. A. M., Hussein, M. H., & Fawzy, M. S. (2017) · Tumor Biology · doi:10.1177/1010428317726842 · Cited by 41
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs
Haas, B., Klinger, V., Keksel, C., Bonigut, V., Kiefer, D., Caspers, J., Walther, J., Wos-Maganga, M., Weickhardt, S., Röhn, G., et al. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0565-4 · Cited by 41
Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges
He, H., Shao, X., Li, Y., Gihu, R., Xie, H., Zhou, J., & Yan, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.675675 · Cited by 41

Authors: Engelman, J. A.
Affiliations: Massachusetts General Hospital (US)
Corresponding author: Engelman, Jeffrey A.
ORCID: Engelman, Jeffrey A.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-08
Volume: 9
Issue: 8
Pages: 550-562
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2664
OpenAlex: W1977267072
Cited by: 2,445
References: 160
Citations by year: 2026: 60 · 2025: 71 · 2024: 75 · 2023: 102 · 2022: 90 · 2021: 125 · 2020: 146 · 2019: 127 · 2018: 163 · 2017: 172 · 2016: 159 · 2015: 210 · 2014: 211 · 2013: 221 · 2012: 184
FWCI: 13.17
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: PI3K/Akt signaling, PI3K inhibitors, AKT inhibitors, cancer therapy, targeted therapy, drug development, tumor cell survival, treatment resistance
MeSH terms: Antineoplastic Agents, Humans, Neoplasms, Protein Kinases, Signal Transduction, Phosphatidylinositol 3-Kinases, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks